{"id":"hydralazine-and-magnesium-valproate","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydralazine is a direct-acting vasodilator that relaxes vascular smooth muscle and may have immunomodulatory effects. Magnesium valproate (valproic acid) is a histone deacetylase (HDAC) inhibitor that promotes histone acetylation, leading to altered gene expression and potential anti-tumor effects. The combination may work synergistically to inhibit angiogenesis and promote differentiation or apoptosis in cancer cells.","oneSentence":"This combination uses hydralazine as a vasodilator and magnesium valproate as a histone deacetylase inhibitor to modulate vascular function and epigenetic pathways in cancer treatment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:33.524Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not publicly detailed; Phase 3 trial status suggests solid tumor or hematologic malignancy under investigation)"}]},"trialDetails":[{"nctId":"NCT02446652","phase":"PHASE3","title":"Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer","status":"WITHDRAWN","sponsor":"National Institute of Cancerología","startDate":"2015-01-01","conditions":"Cervical Cancer","enrollment":""},{"nctId":"NCT00532818","phase":"PHASE3","title":"Hydralazine Valproate for Cervical Cancer","status":"UNKNOWN","sponsor":"National Institute of Cancerología","startDate":"2007-07","conditions":"Metastatic Cervical Cancer","enrollment":143},{"nctId":"NCT00533299","phase":"PHASE3","title":"Hydralazine Valproate for Ovarian Cancer","status":"UNKNOWN","sponsor":"National Institute of Cancerología","startDate":"2007-08","conditions":"Ovarian Cancer","enrollment":211},{"nctId":"NCT00404508","phase":"PHASE2","title":"A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Institute of Cancerología","startDate":"2005-09","conditions":"Refractory Solid Tumors","enrollment":15},{"nctId":"NCT00404326","phase":"PHASE2","title":"Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer","status":"COMPLETED","sponsor":"National Institute of Cancerología","startDate":"2005-05","conditions":"Cervical Cancer","enrollment":18},{"nctId":"NCT00395655","phase":"PHASE2","title":"Hydralazine and Valproate Added to Chemotherapy for Breast Cancer","status":"TERMINATED","sponsor":"National Institute of Cancerología","startDate":"2005-06","conditions":"Locally Advanced Breast Cancer","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TRANSKRIP R/L"],"phase":"phase_3","status":"active","brandName":"Hydralazine and magnesium valproate","genericName":"Hydralazine and magnesium valproate","companyName":"National Institute of Cancerología","companyId":"national-institute-of-cancerolog-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses hydralazine as a vasodilator and magnesium valproate as a histone deacetylase inhibitor to modulate vascular function and epigenetic pathways in cancer treatment. Used for Cancer (specific indication not publicly detailed; Phase 3 trial status suggests solid tumor or hematologic malignancy under investigation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}